Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients. Show Notes | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com
Credits
- Written and Produced by: Hannah R. Abrams
- Cover Art and Infographic by: Hannah R. Abrams
- Hosts: Hannah R Abrams, Matthew Watto MD, FACP
- Editor: Clair Morgan of Nodderly.com (audio), Emi Okamoto MD (written)
- Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD
Sponsor: McGraw Hill
Time Stamps
-
00:00 Sponsor
-
00:26 Intro, disclaimer, guest bio
-
02:57 Guest one-liner and Picks of the Week*: Michael Pollan audiobook on Coffee and Caffeine Addiction
-
03:52 SGLT2i definition, background, and why we now consider CV endpoints in diabetes
-
11:16 Sponsor
-
12:00 Tubuloglomerular feedback; Balloon analogy
-
17:40 Other mechanisms for SGLT2i
-
23:05 Back to the case; Risks from SGLT2i; Counseling and Monitoring
-
34:18 SGLT2i for non-diabetic kidney disease; Possible mechanisms: Joel’s caution against early adoption
-
41:42 SGLT2 inhibitors in kidney transplant
-
45:20 Take home points and picks for the SGLT2 inhibitor region
-
49:50 Outro
